TScan Therapeutics, Inc. (TCRX) Total Assets by Year
TScan Therapeutics, Inc. closed fiscal year 2025 with $228.8M in total assets, $105.7M in total liabilities and $123.1M in shareholder equity. This represents a decrease of 38.4% from the prior fiscal year. The table below carries 6 fiscal years, from 2020 to 2025, and the quarters TScan Therapeutics, Inc. has filed alongside them.
Annual figures, oldest first. Point at a bar to read its period.
TCRX Balance Sheet by Fiscal Year
Figures are as reported in USD. Each change compares the year with the year before it, and each column links to the filing it was taken from.
| Metric | FY2510-K | FY2410-K | FY2310-K | FY2210-K | FY2110-K | FY2010-K |
|---|---|---|---|---|---|---|
| Total Assets | $228.8M-38.4% | $371.1M+36.4% | $272.1M+36.7% | $199.1M+5.8% | $188.1M+278.2% | $49.7M |
| Total Liabilities | $105.7M-18.8% | $130.1M+7.3% | $121.3M+21.7% | $99.7M+264.7% | $27.3M-70.4% | $92.2M |
| Total Equity | $123.1M-48.9% | $241.0M+59.7% | $150.9M+51.7% | $99.4M-38.2% | $160.8M+478.6% | -$42.5M |
TCRX Balance Sheet by Quarter
Figures are as reported in USD. Each change compares the quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q | Q2'2410-Q | Q1'2410-Q | Q4'2310-K | Q3'2310-Q |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | $171.5M-42.6% | $202.0M-39.3% | $228.8M-38.4% | $262.2M-24.7% | $298.6M-20.4% | $332.7M+38.1% | $371.1M+36.4% | $348.0M+19.4% | $374.9M+18.3% | $240.8M+38.7% | $272.1M+36.7% | $291.4M+76.1% |
| Total Liabilities | $102.4M-15.9% | $105.1M-14.2% | $105.7M-18.8% | $118.2M-0.6% | $121.8M+1.8% | $122.5M+3.9% | $130.1M+7.3% | $118.9M-2.8% | $119.7M-5.3% | $117.9M+23.3% | $121.3M+21.7% | $122.4M+150.9% |
| Total Equity | $69.0M-60.9% | $96.9M-53.9% | $123.1M-48.9% | $144.0M-37.1% | $176.7M-30.8% | $210.2M+70.9% | $241.0M+59.7% | $229.1M+35.6% | $255.2M+33.9% | $123.0M+57.6% | $150.9M+51.7% | $169.0M+44.8% |
What total assets means
Total assets is everything the company owns on the balance sheet date, total liabilities is everything it owes, and the difference between them is the equity that belongs to shareholders.
More TScan Therapeutics, Inc. financials
Frequently Asked Questions
What was TScan Therapeutics, Inc.'s total assets in fiscal year 2025?
TScan Therapeutics, Inc. closed fiscal year 2025 with $228.8M in total assets, $105.7M in total liabilities and $123.1M in shareholder equity.
How fast is TScan Therapeutics, Inc.'s total assets growing?
TScan Therapeutics, Inc. (TCRX) total assets fell by 38.4% year over year, from $371.1M to $228.8M in fiscal year 2025.
How has TScan Therapeutics, Inc.'s total assets changed over the years?
Across the 6 fiscal years this page covers, TScan Therapeutics, Inc. (TCRX) total assets went from $49.7M in fiscal year 2020 to $228.8M in fiscal year 2025.
What was TScan Therapeutics, Inc.'s total assets in the most recent quarter?
TScan Therapeutics, Inc. (TCRX) reported $171.5M in total assets in Q2 2026. This represents a decrease of 42.6% from the same quarter a year earlier.
What does total assets mean on a financial statement?
Total assets is everything the company owns on the balance sheet date, total liabilities is everything it owes, and the difference between them is the equity that belongs to shareholders. This page lists what TScan Therapeutics, Inc. (TCRX) reported on that line in every period on record.